Lamzede

Velmanase alfa, the active ingredient in Lamzede, is an enzyme replacement therapy presented as a solution for injection for intravenous use. It treats alpha‑mannosidosis, a lysosomal storage disorder caused by deficient alpha‑mannosidase, in patients of all ages with the genetic deficiency.

GNH USA supplies Lamzede as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, ensuring quality and regulatory compliance across markets. The company provides cold‑chain logistics and documentation to support global distribution.

Lamzede provides enzyme replacement therapy for the lysosomal storage disease alpha‑mannosidosis.

Alpha‑mannosidosis: reduces accumulation of mannose‑containing oligosaccharides, improving clinical symptoms and organ function. Respiratory involvement: helps improve lung function and reduces recurrent infections. Neurological involvement: supports stabilization of motor development and hearing function.

Lamzede may be associated with adverse reactions following infusion.

Common Side Effects: - Infusion‑related reactions such as fever, chills, or flushing - Headache or mild dizziness - Nausea or vomiting - Fatigue or malaise - Transient elevation of liver enzymes - Mild rash or pruritus

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity reactions - Significant hepatic dysfunction with marked enzyme elevation - Thrombocytopenia or bleeding disorders - Acute renal impairment or worsening kidney function - Severe respiratory distress or bronchospasm - Immune complex–mediated vasculitis

Before initiating Lamzede therapy, clinicians should consider several safety measures.

Monitoring infusion reactions: observe patients during and after administration for signs of hypersensitivity. Liver function: assess baseline hepatic enzymes and monitor periodically. Renal function: evaluate kidney parameters before and during treatment. Immunogenicity: be aware of potential antibody formation that may affect efficacy. Contraindications: do not administer to patients with known hypersensitivity to velmanase alfa or any excipients. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the solution.

Lamzede may interact with other biologic agents or vaccines.

Major Interactions (Avoid): - Live attenuated vaccines: risk of reduced vaccine efficacy or infection. - Concurrent enzyme replacement therapies: potential for additive immune responses. - Immunosuppressive biologics: may increase risk of severe hypersensitivity.

Moderate Interactions (Monitor Closely): - Other intravenous drugs administered through the same line: assess compatibility. - Anticoagulants: monitor for bleeding if infusion causes platelet changes. - Hepatotoxic agents: watch liver function tests closely. - Renally cleared medications: adjust dosing if renal function declines.